百济神州公告公司产品百悦泽（泽布替尼胶囊）的3期临床研究MANGROVE（BGB-3111-306；NCT0400229

智通财经06-30

百济神州公告公司产品百悦泽（泽布替尼胶囊）的3期临床研究MANGROVE（BGB-3111-306；NCT04002297）取得积极结果。该研究旨在评估百悦泽联合利妥昔单抗对照苯达莫司汀联合利妥昔单抗（BR）用于套细胞淋巴瘤（MCL）成人初治患者一线治疗的效果。MANGROVE是一项全球性、随机、开放性3期临床试验旨在评估百悦泽联合利妥昔单抗对照苯达莫司汀联合利妥昔单抗用于套细胞淋巴瘤成人初治患者...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2647355149?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-30 21:41","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2647355149","market":"us","top_or_hot":-1,"title":"百济神州公告公司产品百悦泽（泽布替尼胶囊）的3期临床研究MANGROVE（BGB-3111-306；NCT0400229","media":"智通财经","content":"<div>\n<p>百济神州公告公司产品百悦泽（泽布替尼胶囊）的3期临床研究MANGROVE（BGB-3111-306；NCT04002297）取得积极结果。该研究旨在评估百悦泽联合利妥昔单抗对照苯达莫司汀联合利妥昔单抗（BR）用于套细胞淋巴瘤（MCL）成人初治患者一线治疗的效果。MANGROVE是一项全球性、随机、开放性3期临床试验旨在评估百悦泽联合利妥昔单抗对照苯达莫司汀联合利妥昔单抗用于套细胞淋巴瘤成人初治患者...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百济神州公告公司产品百悦泽（泽布替尼胶囊）的3期临床研究MANGROVE（BGB-3111-306；NCT0400229</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百济神州公告公司产品百悦泽（泽布替尼胶囊）的3期临床研究MANGROVE（BGB-3111-306；NCT0400229\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-30 21:41 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>百济神州公告公司产品百悦泽（泽布替尼胶囊）的3期临床研究MANGROVE（BGB-3111-306；NCT04002297）取得积极结果。该研究旨在评估百悦泽联合利妥昔单抗对照苯达莫司汀联合利妥昔单抗（BR）用于套细胞淋巴瘤（MCL）成人初治患者一线治疗的效果。MANGROVE是一项全球性、随机、开放性3期临床试验旨在评估百悦泽联合利妥昔单抗对照苯达莫司汀联合利妥昔单抗用于套细胞淋巴瘤成人初治患者...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4526","symbol_name":"热门中概股","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2647355149","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647355149","pubTimestamp":1782826887,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"百济神州公告公司产品百悦泽（泽布替尼胶囊）的3期临床研究MANGROVE（BGB-3111-306；NCT04002297）取得积极结果。该研究旨在评估百悦泽联合利妥昔单抗对照苯达莫司汀联合利妥昔单抗","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4526":"热门中概股","BK4588":"碎股","BK4585":"ETF&股票定投概念","BGB":"BLACKSTONE STRATEGIC CREDIT 2027 TERM FUND","ONC":"百济神州","BK4139":"生物科技"},"translate_title":"BeiGene announced the Phase 3 clinical study MANGROVE (BGB-3111-306; NCT0400229) of the company's product Baiyueze (zanubrutinib capsules)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONC":1.5,"BGB":1.5},"content_text":"百济神州公告公司产品百悦泽（泽布替尼胶囊）的3期临床研究MANGROVE（BGB-3111-306；NCT04002297）取得积极结果。该研究旨在评估百悦泽联合利妥昔单抗对照苯达莫司汀联合利妥昔单抗（BR）用于套细胞淋巴瘤（MCL）成人初治患者一线治疗的效果。MANGROVE是一项全球性、随机、开放性3期临床试验旨在评估百悦泽联合利妥昔单抗对照苯达莫司汀联合利妥昔单抗用于套细胞淋巴瘤成人初治患者治疗的有效性与安全性。该研究在全球176个研究中心入组510例患者。公司计划在即将召开的医学大会上公布MANGROVE研究的完整结果并正与全球监管机构就相关注册申报计划开展沟通计划于2026年下半年进行申报。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647355149","isCrawlerRequest":true}